Back

Valsartan reduces arterial stiffness along with level of soluble ST2 independently of blood pressure changes

28 August 2022 (15:15 - 16:00)
Organised by:
Congress Presentation Part of: Hypertension - Pharmacotherapy Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Andrzej Tomasik

The Medical University of Silesia, Zabrze (Poland)

7 More presentations in this session

Presentation thumbnail
Intensive reduction of high normal blood pressures: PRINT-TAHA9 randomized clinical trial
Associate Professor A. Attar (Shiraz, IR)
Abstract Slides
Presentation thumbnail
Results from a phase 1 multiple ascending dose study demonstrating safety and selectivity of aldosterone synthase inhibitor CIN-107
Doctor M. Freeman (Boston, US)
Abstract Slides
Presentation thumbnail
Differentiated approach to the treatment of uncomplicated hypertensive crisis
Doctor M. Sadulloeva (Tashkent, UZ)
Abstract Slides
Presentation thumbnail
Blockade of the renin-angiotensin system as a therapeutic target of NAFLD: results of an experimental model of hypercholesterolemia
Professor D. Bertolim Precoma (Campina Grande do Sul, BR)
Abstract Slides
Presentation thumbnail
Hydrochlorothiazide does not lead to phototoxic reactions and DNA damage in healthy volunteers the HCTox study
Doctor F. Goetzinger (Basel, CH)
Abstract Slides

Access the full session

Session thumbnail
Hypertension - Pharmacotherapy

The Event

Event poster

ESC Congress 2022

28 August 2022 15:15 CET
You may be interested in
thumbnail
Congress Session
Challenges in hypertension management
thumbnail
Webinar
Management of blood pressure: selected case-based advice
thumbnail
Congress Presentation
Add-on treatment with zilebesiran for inadequately controlled hypertension: KARDIA-2 RCT

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources